Julia Braverman

2.2k total citations
55 papers, 1.3k citations indexed

About

Julia Braverman is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Julia Braverman has authored 55 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 8 papers in Pathology and Forensic Medicine and 7 papers in Genetics. Recurrent topics in Julia Braverman's work include CAR-T cell therapy research (16 papers), Lymphoma Diagnosis and Treatment (6 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (5 papers). Julia Braverman is often cited by papers focused on CAR-T cell therapy research (16 papers), Lymphoma Diagnosis and Treatment (6 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (5 papers). Julia Braverman collaborates with scholars based in United States, Spain and United Kingdom. Julia Braverman's co-authors include Howard J. Shaffer, David DeSteno, Derek D. Rucker, Duane T. Wegener, Richard E. Petty, Monica Y. Bartlett, Peter Salovey, Julien Dedier, Sarah E. Nelson and Debi A. LaPlante and has published in prestigious journals such as Journal of Personality and Social Psychology, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Julia Braverman

51 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Julia Braverman United States	16	383	355	177	171	166	55	1.3k
R. Brian Giesler United States	22	378 1.0×	588 1.7×	299 1.7×	585 3.4×	137 0.8×	29	2.1k
Tove I. Dahl Norway	13	211 0.6×	377 1.1×	189 1.1×	312 1.8×	223 1.3×	29	1.3k
Shoshana Shiloh Israel	26	306 0.8×	520 1.5×	126 0.7×	257 1.5×	28 0.2×	90	2.4k
Catherine Johnson United States	19	454 1.2×	285 0.8×	114 0.6×	111 0.6×	361 2.2×	67	1.5k
John P. Keating New Zealand	23	334 0.9×	633 1.8×	59 0.3×	408 2.4×	73 0.4×	69	2.2k
Fiona A. White Australia	30	415 1.1×	1.1k 3.2×	88 0.5×	848 5.0×	34 0.2×	77	2.6k
Leonard A. White United States	20	560 1.5×	418 1.2×	272 1.5×	468 2.7×	45 0.3×	46	2.0k
Thomas Powell United States	15	84 0.2×	515 1.5×	87 0.5×	81 0.5×	41 0.2×	41	1.1k
Linda A. Sullivan United States	16	295 0.8×	637 1.8×	130 0.7×	431 2.5×	103 0.6×	26	1.5k
Rose Marie Ward United States	27	880 2.3×	438 1.2×	129 0.7×	464 2.7×	42 0.3×	109	2.3k

Countries citing papers authored by Julia Braverman

Since Specialization

Citations

This map shows the geographic impact of Julia Braverman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julia Braverman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julia Braverman more than expected).

Fields of papers citing papers by Julia Braverman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julia Braverman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julia Braverman. The network helps show where Julia Braverman may publish in the future.

Co-authorship network of co-authors of Julia Braverman

This figure shows the co-authorship network connecting the top 25 collaborators of Julia Braverman. A scholar is included among the top collaborators of Julia Braverman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julia Braverman. Julia Braverman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Braverman, Julia, Gill Worthy, James W. Shaw, et al.. (2024). A Review of Meaningful Change Thresholds for EORTC QLQ-C30 and FACT-G Within Oncology. Value in Health. 27(4). 458–468. 4 indexed citations

Cella, David, Don Husereau, Bellinda L. King‐Kallimanis, et al.. (2024). Administering selected subscales of patient-reported outcome questionnaires to reduce patient burden and increase relevance: a position statement on a modular approach. Quality of Life Research. 33(4). 1075–1084. 3 indexed citations

Hsu, Fu-Shun, et al.. (2024). BEING ATTACK-FREE WITH GARADACIMAB IMPROVES QUALITY OF LIFE IN PATIENTS WITH HEREDITARY ANGIOEDEMA. Annals of Allergy Asthma & Immunology. 133(6). S33–S34.

Itzler, Robbin, et al.. (2024). An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema. Orphanet Journal of Rare Diseases. 19(1). 241–241. 2 indexed citations

Gordon, Leo I., Fei‐Fei Liu, Julia Braverman, et al.. (2023). Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study. Haematologica. 109(3). 857–866. 6 indexed citations

Delforge, Michel, Paula Rodríguez‐Otero, Nina Shah, et al.. (2023). Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial. Leukemia Research. 129. 107074–107074. 11 indexed citations

Abramson, Jeremy S., Scott R. Solomon, Jon Arnason, et al.. (2022). Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor T Cell Therapy, Compared with Standard of Care (SOC) Using Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study. Transplantation and Cellular Therapy. 28(3). S188–S189.

Linhares, Yuliya, Fei‐Fei Liu, Mohamad Cherry, et al.. (2022). Lisocabtagene Maraleucel (Liso-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Treated As Outpatients or Inpatients in the Community/Nonuniversity Setting: Patient-Reported Outcomes/Health-Related Quality of Life from the Outreach Study. Blood. 140(Supplement 1). 10930–10931. 1 indexed citations

Shah, Nina, Michel Delforge, Jesús F. San Miguel, et al.. (2022). Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial. Leukemia Research. 120. 106921–106921. 9 indexed citations

10.

Abramson, Jeremy S., Patrick B. Johnston, Manali Kamdar, et al.. (2022). Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL. Blood Advances. 6(23). 5969–5979. 17 indexed citations

11.

Braverman, Julia, et al.. (2021). PCN221 Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy: Qualitative Analyses of Early Post-Treatment Interviews With Relapsed and Refractory Multiple Myeloma (RRMM) Patients in the KarMMa Clinical Trial. Value in Health. 24. S61–S61. 1 indexed citations

12.

Black, Ryan A., et al.. (2018). Measurement of Quality of Life in Patients with Mycosis Fungoides/Sézary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument. Journal of Medical Internet Research. 21(1). e11302–e11302. 13 indexed citations

13.

Kelman, Ariella, et al.. (2016). Communicating laboratory test results for rheumatoid factor: what do patients and physicians want?. Patient Preference and Adherence. Volume 10. 2501–2517. 18 indexed citations

14.

Braverman, Julia, et al.. (2016). Patients’ motivations and interest in research: characteristics of volunteers for patient-led projects on PatientsLikeMe. Research Involvement and Engagement. 2(1). 33–33. 22 indexed citations

15.

Braverman, Julia, et al.. (2015). Patients’ Experiences With Mycosis Fungoides/Sézary Syndrome - Cutaneous T-Cell Lymphoma (Mf/Ss-Ctcl): Evidence From Qualitative Research Of A Patient Reported Outcome (Pro) Measure Developed On An Online Research Platform. Value in Health. 18(3). A25–A25. 3 indexed citations

16.

Braverman, Julia, et al.. (2014). Accuracy of self-reported versus actual online gambling wins and losses.. Psychological Assessment. 26(3). 865–877. 67 indexed citations

17.

Braverman, Julia, Debi A. LaPlante, Sarah E. Nelson, & Howard J. Shaffer. (2013). Using cross-game behavioral markers for early identification of high-risk internet gamblers.. Psychology of Addictive Behaviors. 27(3). 868–877. 62 indexed citations

18.

Braverman, Julia, Richard A. LaBrie, & Howard J. Shaffer. (2011). A taxometric analysis of actual internet sports gambling behavior.. Psychological Assessment. 23(1). 234–244. 23 indexed citations

19.

Braverman, Julia & Howard J. Shaffer. (2010). How do gamblers start gambling: identifying behavioural markers for high-risk internet gambling. European Journal of Public Health. 22(2). 273–278. 127 indexed citations

20.

DeSteno, David, Richard E. Petty, Derek D. Rucker, Duane T. Wegener, & Julia Braverman. (2004). Discrete Emotions and Persuasion: The Role of Emotion-Induced Expectancies.. Journal of Personality and Social Psychology. 86(1). 43–56. 234 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact